2 Minute Quick Tips from the APSHO Experts

APs: Need some clinical advice? Got 2 minutes? Watch our clinical oncology experts talk about the latest topics that will get you up to speed on current advances in the field. Here you’ll find a range of topics where you can increase your knowledge quickly and then, when you have more than 2 minutes, you can participate in a deeper dive on each topic by accessing the full accredited version at JADPRO CE. Come back often as we are continually updating our 2 minute tips!


Search by:

What are the commonly used systemic agents?

Leah Clark, MS, ARNP

Watch Video


Main Session: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Leah Clark, MS, ARNP, on soft-tissue sarcomas: a multidisciplinary team approach.

What are key strategies for managing AML in older adults?

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD

Watch Video


Main Session: Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD, on managing myeloid malignancies.

What are the indications of a germline predisposition in a patient with a known or suspected myeloid malignancy?

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD

Watch Video


Main Session: Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD, on managing myeloid malignancies.

How do I select patients for treatment with extended adjuvant therapies such as neratinib?

G. Thomas Budd, MD

Watch Video


Main Session: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

What are the mechanisms of action for novel extended adjuvant therapies?

G. Thomas Budd, MD

Watch Video


Main Session: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

What are the procedures to identify and overcome resistance to targeted treatments?

Beth Eaby-Sandy, MSN, CRNP, OCN

Watch Video


Main Session: Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Beth Eaby-Sandy, MSN, CRNP, OCN, on advances in targeted treatments for non–small cell lung cancer.

What are the tools used to predict response to targeted treatments for colorectal cancer?

Michael Hall, MD

Watch Video


Main Session: Hereditary Aspects of Colorectal Cancer

Michael Hall, MD, on hereditary colorectal cancer.

Why do I need to use loperamide when managing diarrhea in patients treated with neratinib?

Lee S. Schwartzberg, MD

Watch Video


Main Session: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Lee S. Schwartzberg, MD, of West Cancer Center, on advances in extended adjuvant therapy for HER2+ breast cancer.

What are the screening tests for Lynch syndrome, and how do you interpret the results?

Heather Hampel, MS, LGC, and Michael Hall, MD

Watch Video


Main Session: Hereditary Aspects of Colorectal Cancer

Heather Hampel, MS, LGC, and Michael Hall, MD, on hereditary colorectal cancer.

How do you identify patients at risk for Lynch syndrome?

Heather Hampel, MS, LGC

Watch Video


Main Session: Hereditary Aspects of Colorectal Cancer

Heather Hampel, MS, LGC, on hereditary colorectal cancer.

How are patients selected for CAR-T therapy?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on hematologic cancers: drug updates.

What are the most recently approved medications for managing hematologic malignancies?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on hematologic cancers: drug updates.

For which immune-related adverse events is it important to consult specialty services early?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

How do you educate patients about what to expect in terms of how their disease will respond to immunotherapy?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

What do you tell patients about the side effects they may experience?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

What are the elements of a multidisciplinary approach to treating patients with soft-tissue sarcomas?

David Johnson, PA-C

Watch Video


Main Session: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

David Johnson, PA-C, on soft-tissue sarcomas: a multidisciplinary team approach.

What is the clinical relevance of FLT3 and IDH2 mutations in AML?

Sandy Kurtin, PhDc, ANP-C, AOCN

Watch Video


Main Session: A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Sandy Kurtin, PhDc, ANP-C, AOCN, on treating patients with AML.

What is the best strategy for managing minimal residual disease?

Hans C. Lee, MD

Watch Video


Main Session: Risk Stratification in Multiple Myeloma: Putting the Pieces Together

Hans C. Lee, MD, on risk stratification in multiple myeloma.

What information will help patients recognize immune-related toxicities?

Emily Lemke, DNP, AGPCNP-BC, AOCNP

Watch Video


Main Session: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Emily Lemke, DNP, AGPCNP-BC, AOCNP, on managing patients with urothelial carcinomas of the bladder.

What are the signs and symptoms of serious adverse effects linked with newly approved solid tumor drugs?

Edward Li, PharmD, MPH, BCOP

Watch Video


Main Session: New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Edward Li, PharmD, MPH, BCOP, on solid tumors: new drug approvals.

What data from clinical trials do the FDA consider when approving new drugs for solid tumors?

Edward Li, PharmD, MPH, BCOP

Watch Video


Main Session: New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Edward Li, PharmD, MPH, BCOP, on solid tumors: new drug approvals.

What type of patients are the best candidates for adjuvant radiation therapy?

Arash Naghavi, MD

Watch Video


Main Session: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Arash Naghavi, MD, on soft-tissue sarcomas: a multidisciplinary team approach.

What is the best way to explain to patients the role of immunotherapies in treating their disease?

Amishi Shah, MD

Watch Video


Main Session: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Amishi Shah, MD, on managing patients with urothelial carcinomas of the bladder.

What are the differences between immunotherapeutic and chemotherapeutic agents?

Amishi Shah, MD

Watch Video


Main Session: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Amishi Shah, MD, on managing patients with urothelial carcinomas of the bladder.

What are the best ways to manage side effects associated with EGFR and ALK inhibitors?

Beth Eaby-Sandy, MSN, CRNP, OCN, and Elizabeth Waxman, RN, MSN, AOCN, ANP-BC

Watch Video


Main Session: Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Beth Eaby-Sandy, MSN, CRNP, OCN, and Elizabeth Waxman, RN, MSN, AOCN, ANP-BC, on advances in targeted treatments for non–small cell lung cancer.

What side effects should practitioners be aware of with AML?

Gabrielle Zecha, PA-C, MHA

Watch Video


Main Session: A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Gabrielle Zecha, PA-C, MHA, on treating patients with acute myeloid leukemia.

How do you manage toxicities of immunotherapeutic agents?

Mollie Reed, MSN, RN, ACNP-BC

Watch Video

Mollie Reed, MSN, RN, ACNP-BC, of Tennessee Oncology, on treating patients with immunotherapy.

How do I distinguish between prescribed drugs, parent biologics, and competing biosimilars?

Kelley Mayden, MSN, FNP, AOCNP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How does a biosimilar compare to its reference product?

Kelley Mayden, MSN, FNP, AOCNP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

What are the biosimilars with current or pending approval from the FDA?

Christopher J. Campen, PharmD, BCOP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

Is it important for me to be involved in post-market studies of biosimilars?

Christopher J. Campen, PharmD, BCOP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How do you educate patients about the timing of early and latent side effects?

Mollie Reed, MSN, RN, ACNP-BC

Watch Video


Main Session: Overview of Immunotherapy

What cancers are most likely to respond to immunotherapy?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

What are the mechanisms of action and adverse effects of these agents?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?

Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Overview of Immunotherapy

When should you image patients to assess response to immunotherapy?

Mollie Reed, MSN, RN, ACNP-BC

Watch Video


Main Session: Overview of Immunotherapy

Is programmed cell death ligand 1 (PD-L1) testing necessary?

Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Overview of Immunotherapy

What are the mechanisms of action of targeted treatments and immunotherapies?

Whitney Lewis

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What is the current thinking on diagnosis and treatment of patients with squamous cell NSCLC?

Frank E. Mott

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are the genetic variants in NSCLC, and how are they used to select treatment?

Frank E. Mott

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you interpret a patient’s therapeutic response to treatment?

Melinda Oliver

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you identify and manage adverse events?

Melinda Oliver

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are some of the emerging therapies and their mechanisms of action?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

How do you select and sequence treatments in the upfront and relapsed/refractory settings?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What are the best ways to help patients adhere to oral therapies?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What is the role of the advanced practitioner in the cancer care team?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What are some of the emerging therapies and their mechanisms of action?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

What should you be aware of when monitoring for toxicities linked with newer agents?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

How do you optimize patient outcomes when adverse events occur?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here